Cargando…
A biomarker study in Peruvian males with breast cancer
BACKGROUND: Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) exp...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546657/ https://www.ncbi.nlm.nih.gov/pubmed/34733614 http://dx.doi.org/10.5306/wjco.v12.i10.926 |
_version_ | 1784590230334996480 |
---|---|
author | Castaneda, Carlos A Castillo, Miluska Bernabe, Luis A Sanchez, Joselyn Torres, Ebert Suarez, Nancy Tello, Katherine Fuentes, Hugo Dunstan, Jorge De La Cruz, Miguel Cotrina, Jose Manuel Abugattas, Julio Guerra, Henry Gomez, Henry L |
author_facet | Castaneda, Carlos A Castillo, Miluska Bernabe, Luis A Sanchez, Joselyn Torres, Ebert Suarez, Nancy Tello, Katherine Fuentes, Hugo Dunstan, Jorge De La Cruz, Miguel Cotrina, Jose Manuel Abugattas, Julio Guerra, Henry Gomez, Henry L |
author_sort | Castaneda, Carlos A |
collection | PubMed |
description | BACKGROUND: Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) expression, and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC. There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC. AIM: To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population. METHODS: This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018. Standard pathological features, TIL levels, MMR proteins, AR immunohistochemistry staining, and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material. Percentage of AR and estrogen receptor (ER) positive cells was additionally calculated by software after slide scanning. Statistical analyses included association tests, intraclass correlation test and Kaplan Meier overall survival curves. RESULTS: The median age was 63 years and most cases were ER-positive (85.7%), HER2 negative (87.2%), Luminal-A phenotype (60%) and clinical stage II (41.5%) among our male breast tumors. Median TIL was 10% and higher levels tended to be associated with Luminal-B phenotype and higher grade. AR-positive was found in 85.3% and was correlated with ER (intraclass index of 0.835, P < 0.001). Loss of MMR proteins was found in 15.4% and PIK3CA mutation (H1047R) in 14.3% (belonged to the Luminal-A phenotype). Loss of MMR proteins was associated with AR-negative (P = 0.018) but not with ER (P = 0.43) or TIL (P = 0.84). Early stages (P < 0.001) and lower grade (P = 0.006) were associated with longer overall survival. ER status, phenotype, AR status, TIL level, MMR protein loss nor PIK3CA mutation was not associated with survival (P > 0.05). CONCLUSION: Male BC is usually ER and AR positive, and Luminal-A. MMR loss and PIK3CA mutations are infrequent. Stage and grade predicted overall survival in our South American country population. |
format | Online Article Text |
id | pubmed-8546657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-85466572021-11-02 A biomarker study in Peruvian males with breast cancer Castaneda, Carlos A Castillo, Miluska Bernabe, Luis A Sanchez, Joselyn Torres, Ebert Suarez, Nancy Tello, Katherine Fuentes, Hugo Dunstan, Jorge De La Cruz, Miguel Cotrina, Jose Manuel Abugattas, Julio Guerra, Henry Gomez, Henry L World J Clin Oncol Retrospective Study BACKGROUND: Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) expression, and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC. There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC. AIM: To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population. METHODS: This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018. Standard pathological features, TIL levels, MMR proteins, AR immunohistochemistry staining, and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material. Percentage of AR and estrogen receptor (ER) positive cells was additionally calculated by software after slide scanning. Statistical analyses included association tests, intraclass correlation test and Kaplan Meier overall survival curves. RESULTS: The median age was 63 years and most cases were ER-positive (85.7%), HER2 negative (87.2%), Luminal-A phenotype (60%) and clinical stage II (41.5%) among our male breast tumors. Median TIL was 10% and higher levels tended to be associated with Luminal-B phenotype and higher grade. AR-positive was found in 85.3% and was correlated with ER (intraclass index of 0.835, P < 0.001). Loss of MMR proteins was found in 15.4% and PIK3CA mutation (H1047R) in 14.3% (belonged to the Luminal-A phenotype). Loss of MMR proteins was associated with AR-negative (P = 0.018) but not with ER (P = 0.43) or TIL (P = 0.84). Early stages (P < 0.001) and lower grade (P = 0.006) were associated with longer overall survival. ER status, phenotype, AR status, TIL level, MMR protein loss nor PIK3CA mutation was not associated with survival (P > 0.05). CONCLUSION: Male BC is usually ER and AR positive, and Luminal-A. MMR loss and PIK3CA mutations are infrequent. Stage and grade predicted overall survival in our South American country population. Baishideng Publishing Group Inc 2021-10-24 2021-10-24 /pmc/articles/PMC8546657/ /pubmed/34733614 http://dx.doi.org/10.5306/wjco.v12.i10.926 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Retrospective Study Castaneda, Carlos A Castillo, Miluska Bernabe, Luis A Sanchez, Joselyn Torres, Ebert Suarez, Nancy Tello, Katherine Fuentes, Hugo Dunstan, Jorge De La Cruz, Miguel Cotrina, Jose Manuel Abugattas, Julio Guerra, Henry Gomez, Henry L A biomarker study in Peruvian males with breast cancer |
title | A biomarker study in Peruvian males with breast cancer |
title_full | A biomarker study in Peruvian males with breast cancer |
title_fullStr | A biomarker study in Peruvian males with breast cancer |
title_full_unstemmed | A biomarker study in Peruvian males with breast cancer |
title_short | A biomarker study in Peruvian males with breast cancer |
title_sort | biomarker study in peruvian males with breast cancer |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546657/ https://www.ncbi.nlm.nih.gov/pubmed/34733614 http://dx.doi.org/10.5306/wjco.v12.i10.926 |
work_keys_str_mv | AT castanedacarlosa abiomarkerstudyinperuvianmaleswithbreastcancer AT castillomiluska abiomarkerstudyinperuvianmaleswithbreastcancer AT bernabeluisa abiomarkerstudyinperuvianmaleswithbreastcancer AT sanchezjoselyn abiomarkerstudyinperuvianmaleswithbreastcancer AT torresebert abiomarkerstudyinperuvianmaleswithbreastcancer AT suareznancy abiomarkerstudyinperuvianmaleswithbreastcancer AT tellokatherine abiomarkerstudyinperuvianmaleswithbreastcancer AT fuenteshugo abiomarkerstudyinperuvianmaleswithbreastcancer AT dunstanjorge abiomarkerstudyinperuvianmaleswithbreastcancer AT delacruzmiguel abiomarkerstudyinperuvianmaleswithbreastcancer AT cotrinajosemanuel abiomarkerstudyinperuvianmaleswithbreastcancer AT abugattasjulio abiomarkerstudyinperuvianmaleswithbreastcancer AT guerrahenry abiomarkerstudyinperuvianmaleswithbreastcancer AT gomezhenryl abiomarkerstudyinperuvianmaleswithbreastcancer AT castanedacarlosa biomarkerstudyinperuvianmaleswithbreastcancer AT castillomiluska biomarkerstudyinperuvianmaleswithbreastcancer AT bernabeluisa biomarkerstudyinperuvianmaleswithbreastcancer AT sanchezjoselyn biomarkerstudyinperuvianmaleswithbreastcancer AT torresebert biomarkerstudyinperuvianmaleswithbreastcancer AT suareznancy biomarkerstudyinperuvianmaleswithbreastcancer AT tellokatherine biomarkerstudyinperuvianmaleswithbreastcancer AT fuenteshugo biomarkerstudyinperuvianmaleswithbreastcancer AT dunstanjorge biomarkerstudyinperuvianmaleswithbreastcancer AT delacruzmiguel biomarkerstudyinperuvianmaleswithbreastcancer AT cotrinajosemanuel biomarkerstudyinperuvianmaleswithbreastcancer AT abugattasjulio biomarkerstudyinperuvianmaleswithbreastcancer AT guerrahenry biomarkerstudyinperuvianmaleswithbreastcancer AT gomezhenryl biomarkerstudyinperuvianmaleswithbreastcancer |